Physician profile
Patrick Dale
NPI 1861889156
$31,569.25
in general payments reported to CMS, 2019-2025
25 companies · $1,350 in 2025
The $1,350 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25K · 2021: $129 · 2022: $2,110 · 2023: $1,519 · 2024: $1,461 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,330.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $25,000.00 | 2020 | |
| Medtronic, INC. | $2,573.74 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II, Primo Mri Dr Surescan |
| Boston Scientific Corporation | $1,193.81 | 2023-2025 | Farapulse, Ingevity+, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $740.94 | 2023 | Gallant, Ensite, Assurity |
| Pfizer INC. | $199.62 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.53 | 2023-2025 | Jardiance |
| Cvrx, INC. | $163.42 | 2023 | Barostim Neo System |
| Atricure, INC. | $156.81 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $148.22 | 2023-2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $138.79 | 2024-2025 | Onpattro, Amvuttra |
| Biosense Webster, INC. | $133.19 | 2023-2025 | Carto 3, Nuvision Ice Catheter |
| Abiomed | $129.50 | 2023-2024 | Impella |
| Novo Nordisk INC | $117.00 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $114.40 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $94.86 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $71.40 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.80 | 2024-2025 | Lifevest |
| Amgen INC. | $65.31 | 2024-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $64.13 | 2025 | Assure Wcd |
| Heartflow, INC. | $55.83 | 2024-2025 | |
| Inspire Medical Systems, INC. | $44.74 | 2024-2025 | Inspire |
| Impulse Dynamics (USA) INC. | $42.15 | 2024 | Optimizer |
| Scpharmaceuticals INC. | $27.15 | 2024 | |
| Esperion Therapeutics, INC. | $21.53 | 2023 | Nexletol |
| Philips North America LLC | $20.38 | 2025 | Lm Undivided |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.